相关实验视频

Updated: Jul 20, 2025

Author Spotlight: Insights and Innovations in Gene Expression Manipulation Techniques for Choroid Plexus Research

Author Spotlight: Insights and Innovations in Gene Expression Manipulation Techniques for Choroid Plexus Research

Published on: June 16, 2023

可诱导的前列腺素E合成酶 (mPGES-1) 在神经炎症性疾病中

Madison N Sluter¹, Qianqian Li¹, Nelufar Yasmen¹

¹Department of Pharmaceutical Sciences, College of Pharmacy, The University of Tennessee Health Science Center, Memphis, TN 38163, USA.

Experimental biology and medicine (Maywood, N.J.)

|July 29, 2023

概括

向微体质前列腺素E合成酶-1 (mPGES-1) 提供了一种特殊的方法来减少和中风等脑疾病中的神经炎症. 抑制mPGES-1可以减轻有害的炎症反应,并防止神经元受损.

科学领域:

神经科学是一个神经科学.
药理学药理学是指药理学的学科.
炎症研究炎症研究

背景情况:

循环氧化酶 (COX) /前列腺素E2 (PGE2) 途径与神经系统疾病有关.
由于心血管和脑血管的副作用,COX抑制剂具有局限性.
微体质前列腺素E合成酶-1 (mPGES-1) 是特定PGE2抑制的下游目标.

研究的目的:

评估针对神经炎症疾病的mPGES-1的治疗潜力.
研究mPGES-1在,中风和质瘤等疾病中的作用.

主要方法:

对神经系统疾病中COX/PGE2通路和mPGES-1的现有文献的综述.
在临床前模型中分析了在临床前模型中证明mPGES-1抑制作用的研究.

主要成果:

在,中风,质瘤和神经退行性疾病中观察到升高的mPGES-1和PGE2水平.
在和中风中,PGE2有助于兴奋毒性,微质激活和神经炎症.
抑制mPGES-1可降低质体,炎症,心脏病大小,并改善中风模型的结果.
此外,PGE2还促进质瘤细胞的增殖和血脑屏障 (BBB) 的破坏.

结论:

与广泛的COX抑制相比,针对mPGES-1提供了一个更具体的治疗神经炎症的策略.
调节mPGES-1可能为一系列神经炎症特征的神经系统疾病提供治疗效益.

关键词:

血脑屏障 (Blood-Brain Barrier,BBB) 是一个很大的障碍.循环氧化原酶 (COX) 的使用.是一种.质瘤质瘤是一种缺血性中风中风神经退行性疾病的神经退行性疾病神经炎症是一种神经炎症.孕腺素E合成酶 (PGES) 的使用发作发作这些状态性的状态

更多相关视频

Visualizing Impairment of the Endothelial and Glial Barriers of the Neurovascular Unit during Experimental Autoimmune Encephalomyelitis In Vivo

Visualizing Impairment of the Endothelial and Glial Barriers of the Neurovascular Unit during Experimental Autoimmune Encephalomyelitis In Vivo

Published on: March 26, 2019

Author Spotlight: Creating a Versatile Experimental Autoimmune Encephalomyelitis Model Relevant for Both Male and Female Mice

Author Spotlight: Creating a Versatile Experimental Autoimmune Encephalomyelitis Model Relevant for Both Male and Female Mice

Published on: October 13, 2023

相关概念视频

IP3/DAG Signaling Pathway

IP3/DAG Signaling Pathway

Membrane lipids such as phosphatidylinositol (PI) are precursors for several membrane-bound and soluble second messengers. Specific kinases phosphorylate PI and produce phosphorylated inositol phospholipids. One such inositol phospholipids are the phosphatidylinositol-4,5 bisphosphate [PI(4,5)P2], present in the inner half of the lipid bilayer. Upon ligand binding, GPCR stimulates Gq proteins to turn on phospholipase Cꞵ. Activated phospholipase Cꞵ cleaves PI(4,5)P2 and...

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...

Gastritis-II: Pathophysiology

Gastritis-II: Pathophysiology

Gastritis is marked by disruption of the mucosal barrier that usually protects the stomach tissue from digestive juices and manifests in acute and chronic forms.
In acute gastritis, the gastric mucosa becomes swollen and red and undergoes superficial erosion. Superficial ulceration may lead to bleeding.
In chronic gastritis, persistent or repeated insults lead to chronic inflammatory changes and, eventually, thinning or atrophy of the gastric tissue.
Gastritis can stem from various causes, each...